Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 68
Published on October 8, 2016 at 04:30 PM


Study On Occurrence Of type 1 Diabetes

A study led by Dr Nicholas JM Thomas from the University of Exeter Medical School, Exeter, Devon, United Kingdom found that 50 percent of the type 1 diabetes (T1D) cases were developed after 30 years. Researchers reviewed the data from UK Biobank and the results negate the belief that type i diabetes develops in childhood. Researchers found that

The study findings were presented to the European Association for the Study of Diabetes (EASD).

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. About type 1 disease (T1D) And type 2 Diabetes (T2D)
2. Device To Release Drugs In Eye
3. Treatment With Patient Specific Drugs
4. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca

 

FDA Approves Medtronic Artificial Pancreas MiniMed 670G

Food and Drug Administration (FDA) approved MiniMed 670G artificial pancreas device made by Medtronic. Medtronic filed for FDA approval of MiniMed in June, 2016. The product will be in the market during spring of 2017.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. FDA Approval Of Adlyxin
2. About Medtronic Sugar.IQ
3. Risk To Pancreas Inflammation With Gliptin Treatment
4. About Medtronic MiniMed 630G

 

DPP-4 Inhibitor Linagliptin Tradjenta Prevents Cardiovascular Disease (CVD)

Previous studies shows that overweight and high blood sugar levels causes vascular stiffness (network blood vessels stiffness) and progression of cardiovascular disease (CVD). Women are at more risk compared to men of same age and same health problems. Researchers from University of Missouri School of Medicine observed in mice models that linagliptin diabetes drug is preventing vascular stiffness in obese female mice. Researchers says further research is required to confirm results. Lead author of the study is Dr Vincent DeMarco, an associate professor at MU School of Medicine.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Trials With Tradjenta Linagliptin Drug
2. Cardiovascular Exercise Benefits With Interval Exercise training
3. Dyslipidemia And Risks To Cardiovascular Disease (CVD) And Ischemic Heart Disease (IHD)
4. Device To Detect Deadly Ketones

Linagliptin : Trade names are Tradjenta in United States and Trajenta in other countries. This is a prescription based DPP-4 inhibitor and diabetes drug developed by Boehringer Ingelheim to lower blood sugar levels in type 2 diabetes (T2D) patients. This drug blocks enzyme dipeptidyl peptidase-4 or DPP-four to lower blood sugar levels. Earlier studies shows this drug prevents arterial stiffening conditions such as vascular inflammation.

 

Regular Cycling Prevents Type 2 Diabetes (T2D) And Coronary Heart Disease

A research study results linked cycling exercise to lower risk of development of type 2 diabetes (T2D). Researchers studied about 24,000 men and 28,000 women aged between 50 and 65 years in Denmark and came to following conclusions.

The study results were published in PLOS Medicine Journal. British Medical Association says cycling for 20 miles or 32 km per week reduces risk to coronary heart disease by 50 percent and improves quality of life.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Study With Standing, Sitting and Cycling Activity
2. Tips To Manage type 2 Diabetes (T2D)
3. Coronary Artery Disease And Risks To Coronary Artery Calcification (CAC) Score
4. About Revita DMR Device

 

Link Between LDL-C Drugs And type 2 Diabetes
Researchers studied meta analysis of more than 500,000 adults and found that variants near NPC1L1, PCSK9 and HMGCR and other genes associated with reduction of low-density lipoprotein cholesterol (LDL-C) were linked to adverse metabolic consequences and enhanced risk to development of type 2 diabetes (and weight gain). But researchers says risk to development of coronary heart disease will decrease. LDL-C is a "BAD" cholesterol and is the main cause to development of plaque in the arteries, a risk factor to heart diseases and stroke. Some of the LDL-C lowering drugs in the market are ezetimibe, statins and PCSK9-inhibitors. Senior author of the study is Dr Luca A Lotta of the University of Cambridge, UK and study results were published in JAMA.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Study On Wearable Technology Devices
2. Device To Find Out Internal Inflammation
3. Diabetes Mobile App To Manage Blood Sugar Levels
4. Factors To Prevent Heart Attack

Stroke : Also called as brain attack is caused due to high blood pressure that damages arteries (atherosclerosis and hardening) in the body. Deteriorated arteries in the brain obstruct flow of blood to brain cells. Cells in the brain dies due to non availability of oxygen and glucose and causes permanent damage to brain. High blood pressure increases stroke risk by four to six times. Most of the strokes are ischemic strokes.

 

Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.